Telix Pharmaceuticals Limited
TLX
$9.98
-$0.13-1.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 667.41M | 595.08M | 514.99M | 470.19M | 421.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 667.41M | 595.08M | 514.99M | 470.19M | 421.97M |
| Cost of Revenue | 306.98M | 257.73M | 196.65M | 180.67M | 163.38M |
| Gross Profit | 360.43M | 337.35M | 318.34M | 289.52M | 258.59M |
| SG&A Expenses | 170.59M | 155.37M | 137.24M | 123.55M | 108.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 13.01M | 10.14M | 5.45M | 5.04M | 4.62M |
| Total Operating Expenses | 645.15M | 566.83M | 467.40M | 427.34M | 384.15M |
| Operating Income | 22.26M | 28.25M | 47.58M | 42.85M | 37.82M |
| Income Before Tax | 9.29M | 17.54M | 36.75M | 34.80M | 32.68M |
| Income Tax Expenses | -1.81M | -2.30M | 3.94M | 2.23M | 502.50K |
| Earnings from Continuing Operations | 11.10 | 19.84 | 32.81 | 32.57 | 32.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.10M | 19.84M | 32.81M | 32.57M | 32.18M |
| EBIT | 22.26M | 28.25M | 47.58M | 42.85M | 37.82M |
| EBITDA | 30.60M | 34.67M | 51.33M | 46.62M | 41.61M |
| EPS Basic | 0.03 | 0.05 | 0.09 | 0.09 | 0.09 |
| Normalized Basic EPS | 0.04 | 0.05 | 0.08 | 0.07 | 0.06 |
| EPS Diluted | 0.03 | 0.05 | 0.08 | 0.09 | 0.09 |
| Normalized Diluted EPS | 0.04 | 0.05 | 0.08 | 0.07 | 0.06 |
| Average Basic Shares Outstanding | 1.34B | 1.66B | 1.65B | 1.64B | 1.62B |
| Average Diluted Shares Outstanding | 1.38B | 1.72B | 1.72B | 1.70B | 1.68B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |